Kyorin pays $140M for Japan rights to Edesa’s respiratory drug
Edesa Biotech has partnered with Kyorin Pharmaceutical to bring its late-stage respiratory drug to Japan in a deal worth up to $140 million. Kyorin will handle all local development and commercialization costs, while also gaining a first refusal right for other potential medical uses.
Original image temporarily unavailable
Edesa Biotech has signed a licensing agreement with Japan's Kyorin Pharmaceutical for its anti-TLR4 antibody, paridiprubart, aimed at treating acute respiratory distress syndrome. Kyorin is paying $12 million upfront and could shell out up to $134 million in milestone payments, alongside royalties.
Paridiprubart previously showed promise in a phase 3 study involving COVID-19 patients, prompting Edesa to broaden its focus toward general ARDS. Recent exploratory analyses also suggested the drug could help patients suffering from ARDS and acute kidney injury simultaneously. Kyorin will fully fund local development and plans to leverage its existing respiratory expertise to push the treatment forward in Japan.
View selection rationale
Importance 53/100
About this brief
- Content type
- Research summary
- Source type
- Publisher report
- Original source
- Fierce Biotech ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.